Allan Pantuck, M.D.
Robert Reiter, M.D., M.B.A.
Hong Wu, M.D., Ph.D.
The Genitourinary (GU) Oncology Program encompasses a comprehensive research program to investigate the molecular and immunologic mechanisms responsible for genitourinary cancers (primarily prostate, kidney and bladder), and also to rapidly translate these findings into therapeutic trials. The program seeks to coordinate all clinical activities to deliver optimum care to patients with localized and metastatic tumors. The program area hopes to facilitate the study of new and emerging treatment strategies, especially those translated from basic science research.
- Understand the molecular basis of genitourinary cancers (primarily prostate, kidney and bladder cancer)
- Create mouse models of these cancers
- Perform pre-clinical studies of new therapeutic agents
- Conduct phase I/II clinical trials of novel anti-cancer drugs
Meetings and Events:
- Basic and clinical research group meetings
- Weekly Genitourinary Oncology Tumor Board
- Weekly Kidney Cancer Program Working Group Meeting
- Bi-monthly Prostate Cancer seminar (co-sponsored by Prostate SPORE)
- Monthly Prostate Cancer Journal Club
- Monthly Basic Science Prostate Cancer Group
- Annual Prostate Cancer one-day research retreat
- Intramural speaker series
- External speaker series
Dr. Allan Pantuck, Director (Kidney and Bladder) of the Genitourinary Oncology Program, is an associate professor of urology at the David Geffen School of Medicine at UCLA. Pantuck is also Director of Translational Research of the UCLA Kidney Cancer Program. His lab studies molecular and genetic determinants of immunotherapy response in advanced Renal Cell Carcinoma. Furthermore, his lab collaborates extensively with other research programs, including Harvard University, University of Rennes and University of California, San Francisco. Pantuck holds a Master of Science Degree in Clinical Research and has a major interest devoted to translational research in GU oncology that includes nutrition and chemoprevention, including NIH-funded research of green tea for preventing bladder cancer and the use of pomegranate juice as a treatment for prostate cancer. He is currently the UCLA Principal Investigator of numerous clinical trials for NIH-funded, investigator initiated and industry sponsored clinical trials. He is a member on the UCLA Medical Institutional Review Board (IRB) and the Institutional Scientific Peer Review and Data and Safety Monitoring Committees of UCLA's Jonsson Comprehensive Cancer Center (JCCC). Furthermore, he is a member on the GU committee of the Southwest Oncology Group and has served in an advisory capacity to develop future GU oncology clinical trials for both the Eastern Cooperative Oncology Group and the American College of Surgeons Oncology Group.
Dr. Robert Reiter, a Genitourinary Oncology Program Director (Prostate), is a professor of urology. As a physician-scientist, he is dedicated to translating his basic research into improved methods for detection and treatment of cancer. He worked with Dr. Charles Sawyers to develop the LAPC xenograft models of prostate cancer and his laboratory discovered prostate stem cell antigen (PSCA), a cell surface antigen expressed by a majority of prostate and bladder tumors. Reiter received peer-reviewed funding to determine the prognostic utility of PSCA and to unravel the scientific basis for the efficacy of PSCA antibodies. He has developed a large brachytherapy program at UCLA and is working with colleagues to develop an active laparoscopic prostatectomy program.
Dr. Hong Wu, a Genitourinary Oncology Program Associate Director (Basic Research), is a professor of molecular and medical pharmacology, and a member of the UCLA Molecular Biology Institute. She is Co-Director of the Cancer Stem Cell Program Area of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and Director of the JCCC ES Cell/Transgenic Mice Shared Resource
. She serves as a member of the NCI Mouse Model of Human Cancer Consortium Steering Committee. A major research focus of Wu’s laboratory is to study the molecular mechanism of PTEN controlled tumorigenesis. By generating tissue-specific PTEN deficient animal models, including the prostate cancer model, Wu’s laboratory elucidated the important role of PTEN in regulating stem cell self-renewal, proliferation and survival, as well as its roles in controlling "cancer stem cells." These models have been used for pre-clinical studies of new therapeutic agents and for identifying biomarkers for human prostate cancers.